Clinical Trials Browser

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase 2 Active not recruiting

720 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01898117 2025-11-26

Triple-B

Phase 2 Active not recruiting

304 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Phase 2 Active not recruiting

69 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT04602078 2025-04-24

AUREA

Phase 2 Completed

82 enrolled 20 charts

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

72 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05007613 2025-01-01

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Completed

24 enrolled

Gastrointestinal

Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Metastasis

NCT06099418 2024-09-20

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Phase 2 Withdrawn

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT04984811 2024-03-05

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Phase 2 Active not recruiting

83 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03698461 2024-01-31

CLIMB

Phase 2 Completed

20 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04405349 2023-12-15

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Phase 2 Completed

52 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT03147040 2022-07-19

GELATO

Phase 2 Terminated

23 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03952325 2021-07-30

CONTESSA TRIO

Phase 2 Terminated

294 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

TOMBOLA

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Triple-B

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

AUREA

CRAFT: The NCT-PMO-1602 Phase II Trial

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

IMPRESS-N

CLIMB

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

GELATO

CONTESSA TRIO